Global Fertility Enhancing Treatment 麻豆原创 2025 by Company, Regions, Type and Application, Forecast to 2031

Publication ID:

GIR012508892

Publication Date:

January 22, 2025

Pages:

118

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Fertility Enhancing Treatment market size was valued at US$ 5435 million in 2024 and is forecast to a readjusted size of USD 8165 million by 2031 with a CAGR of 6.1% during review period.
Infertility Drugs are drugs which enhance reproductive fertility. For women, Infertility Drugs is used to stimulate follicle development of the ovary. Agents that enhance ovarian activity can be classified as either Gonadotropin releasing hormone, Estrogen antagonists or Gonadotropins.
Global Fertility Enhancing Treatment key players include Merck, Ferring, MSD, LIVZON, Abbott, etc. Global top five manufacturers hold a share about 60%.
North America is the largest market, with a share over 30%, followed by China, and Europe, both have a share about 40 percent.
In terms of product, Fertility Drugs for Women is the largest segment, with a share over 85%. And in terms of application, the largest application is Drug Stores, followed by Hospitals, Online, etc.
This report is a detailed and comprehensive analysis for global Fertility Enhancing Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Fertility Enhancing Treatment market size and forecasts, in consumption value ($ Million), 2020-2031
Global Fertility Enhancing Treatment market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Fertility Enhancing Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Fertility Enhancing Treatment market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Fertility Enhancing Treatment
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Fertility Enhancing Treatment market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck, Ferring, MSD, LIVZON, Abbott, Bayer Zydus Pharma, 颁丑耻谤肠丑锛咲飞颈驳丑迟, SASMAR, BioFilm,Inc, FAIRHAVEN HEALTH, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Fertility Enhancing Treatment market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Fertility Drugs for Women
Fertility Drugs for Men
OTC Conception Gels/Lubricants
麻豆原创 segment by Application
Hospitals
Drug Stores
Online
麻豆原创 segment by players, this report covers
Merck
Ferring
MSD
LIVZON
Abbott
Bayer Zydus Pharma
颁丑耻谤肠丑锛咲飞颈驳丑迟
SASMAR
BioFilm,Inc
FAIRHAVEN HEALTH
The YES YES Company
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Fertility Enhancing Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Fertility Enhancing Treatment, with revenue, gross margin, and global market share of Fertility Enhancing Treatment from 2020 to 2025.
Chapter 3, the Fertility Enhancing Treatment competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Fertility Enhancing Treatment market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Fertility Enhancing Treatment.
Chapter 13, to describe Fertility Enhancing Treatment research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Fertility Enhancing Treatment by Type
1.3.1 Overview: Global Fertility Enhancing Treatment 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Fertility Enhancing Treatment Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 Fertility Drugs for Women
1.3.4 Fertility Drugs for Men
1.3.5 OTC Conception Gels/Lubricants
1.4 Global Fertility Enhancing Treatment 麻豆原创 by Application
1.4.1 Overview: Global Fertility Enhancing Treatment 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospitals
1.4.3 Drug Stores
1.4.4 Online
1.5 Global Fertility Enhancing Treatment 麻豆原创 Size & Forecast
1.6 Global Fertility Enhancing Treatment 麻豆原创 Size and Forecast by Region
1.6.1 Global Fertility Enhancing Treatment 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Fertility Enhancing Treatment 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Fertility Enhancing Treatment 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Fertility Enhancing Treatment 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Fertility Enhancing Treatment 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Fertility Enhancing Treatment 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Fertility Enhancing Treatment 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 Merck
2.1.1 Merck Details
2.1.2 Merck Major Business
2.1.3 Merck Fertility Enhancing Treatment Product and Solutions
2.1.4 Merck Fertility Enhancing Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Merck Recent Developments and Future Plans
2.2 Ferring
2.2.1 Ferring Details
2.2.2 Ferring Major Business
2.2.3 Ferring Fertility Enhancing Treatment Product and Solutions
2.2.4 Ferring Fertility Enhancing Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Ferring Recent Developments and Future Plans
2.3 MSD
2.3.1 MSD Details
2.3.2 MSD Major Business
2.3.3 MSD Fertility Enhancing Treatment Product and Solutions
2.3.4 MSD Fertility Enhancing Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 MSD Recent Developments and Future Plans
2.4 LIVZON
2.4.1 LIVZON Details
2.4.2 LIVZON Major Business
2.4.3 LIVZON Fertility Enhancing Treatment Product and Solutions
2.4.4 LIVZON Fertility Enhancing Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 LIVZON Recent Developments and Future Plans
2.5 Abbott
2.5.1 Abbott Details
2.5.2 Abbott Major Business
2.5.3 Abbott Fertility Enhancing Treatment Product and Solutions
2.5.4 Abbott Fertility Enhancing Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Abbott Recent Developments and Future Plans
2.6 Bayer Zydus Pharma
2.6.1 Bayer Zydus Pharma Details
2.6.2 Bayer Zydus Pharma Major Business
2.6.3 Bayer Zydus Pharma Fertility Enhancing Treatment Product and Solutions
2.6.4 Bayer Zydus Pharma Fertility Enhancing Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Bayer Zydus Pharma Recent Developments and Future Plans
2.7 颁丑耻谤肠丑锛咲飞颈驳丑迟
2.7.1 颁丑耻谤肠丑锛咲飞颈驳丑迟 Details
2.7.2 颁丑耻谤肠丑锛咲飞颈驳丑迟 Major Business
2.7.3 颁丑耻谤肠丑锛咲飞颈驳丑迟 Fertility Enhancing Treatment Product and Solutions
2.7.4 颁丑耻谤肠丑锛咲飞颈驳丑迟 Fertility Enhancing Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 颁丑耻谤肠丑锛咲飞颈驳丑迟 Recent Developments and Future Plans
2.8 SASMAR
2.8.1 SASMAR Details
2.8.2 SASMAR Major Business
2.8.3 SASMAR Fertility Enhancing Treatment Product and Solutions
2.8.4 SASMAR Fertility Enhancing Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 SASMAR Recent Developments and Future Plans
2.9 BioFilm,Inc
2.9.1 BioFilm,Inc Details
2.9.2 BioFilm,Inc Major Business
2.9.3 BioFilm,Inc Fertility Enhancing Treatment Product and Solutions
2.9.4 BioFilm,Inc Fertility Enhancing Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 BioFilm,Inc Recent Developments and Future Plans
2.10 FAIRHAVEN HEALTH
2.10.1 FAIRHAVEN HEALTH Details
2.10.2 FAIRHAVEN HEALTH Major Business
2.10.3 FAIRHAVEN HEALTH Fertility Enhancing Treatment Product and Solutions
2.10.4 FAIRHAVEN HEALTH Fertility Enhancing Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 FAIRHAVEN HEALTH Recent Developments and Future Plans
2.11 The YES YES Company
2.11.1 The YES YES Company Details
2.11.2 The YES YES Company Major Business
2.11.3 The YES YES Company Fertility Enhancing Treatment Product and Solutions
2.11.4 The YES YES Company Fertility Enhancing Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 The YES YES Company Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Fertility Enhancing Treatment Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Fertility Enhancing Treatment by Company Revenue
3.2.2 Top 3 Fertility Enhancing Treatment Players 麻豆原创 Share in 2024
3.2.3 Top 6 Fertility Enhancing Treatment Players 麻豆原创 Share in 2024
3.3 Fertility Enhancing Treatment 麻豆原创: Overall Company Footprint Analysis
3.3.1 Fertility Enhancing Treatment 麻豆原创: Region Footprint
3.3.2 Fertility Enhancing Treatment 麻豆原创: Company Product Type Footprint
3.3.3 Fertility Enhancing Treatment 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Fertility Enhancing Treatment Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Fertility Enhancing Treatment 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Fertility Enhancing Treatment Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Fertility Enhancing Treatment 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Fertility Enhancing Treatment Consumption Value by Type (2020-2031)
6.2 North America Fertility Enhancing Treatment 麻豆原创 Size by Application (2020-2031)
6.3 North America Fertility Enhancing Treatment 麻豆原创 Size by Country
6.3.1 North America Fertility Enhancing Treatment Consumption Value by Country (2020-2031)
6.3.2 United States Fertility Enhancing Treatment 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Fertility Enhancing Treatment 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Fertility Enhancing Treatment 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Fertility Enhancing Treatment Consumption Value by Type (2020-2031)
7.2 Europe Fertility Enhancing Treatment Consumption Value by Application (2020-2031)
7.3 Europe Fertility Enhancing Treatment 麻豆原创 Size by Country
7.3.1 Europe Fertility Enhancing Treatment Consumption Value by Country (2020-2031)
7.3.2 Germany Fertility Enhancing Treatment 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Fertility Enhancing Treatment 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Fertility Enhancing Treatment 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Fertility Enhancing Treatment 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Fertility Enhancing Treatment 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Fertility Enhancing Treatment Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Fertility Enhancing Treatment Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Fertility Enhancing Treatment 麻豆原创 Size by Region
8.3.1 Asia-Pacific Fertility Enhancing Treatment Consumption Value by Region (2020-2031)
8.3.2 China Fertility Enhancing Treatment 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Fertility Enhancing Treatment 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Fertility Enhancing Treatment 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Fertility Enhancing Treatment 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Fertility Enhancing Treatment 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Fertility Enhancing Treatment 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Fertility Enhancing Treatment Consumption Value by Type (2020-2031)
9.2 South America Fertility Enhancing Treatment Consumption Value by Application (2020-2031)
9.3 South America Fertility Enhancing Treatment 麻豆原创 Size by Country
9.3.1 South America Fertility Enhancing Treatment Consumption Value by Country (2020-2031)
9.3.2 Brazil Fertility Enhancing Treatment 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Fertility Enhancing Treatment 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Fertility Enhancing Treatment Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Fertility Enhancing Treatment Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Fertility Enhancing Treatment 麻豆原创 Size by Country
10.3.1 Middle East & Africa Fertility Enhancing Treatment Consumption Value by Country (2020-2031)
10.3.2 Turkey Fertility Enhancing Treatment 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Fertility Enhancing Treatment 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Fertility Enhancing Treatment 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Fertility Enhancing Treatment 麻豆原创 Drivers
11.2 Fertility Enhancing Treatment 麻豆原创 Restraints
11.3 Fertility Enhancing Treatment Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Fertility Enhancing Treatment Industry Chain
12.2 Fertility Enhancing Treatment Upstream Analysis
12.3 Fertility Enhancing Treatment Midstream Analysis
12.4 Fertility Enhancing Treatment Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

Merck
Ferring
MSD
LIVZON
Abbott
Bayer Zydus Pharma
颁丑耻谤肠丑锛咲飞颈驳丑迟
SASMAR
BioFilm,Inc
FAIRHAVEN HEALTH
The YES YES Company

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.